DR. HUTCHISON, MBChB, PGA, MRCP, PhD
Hasting Memorial Hospital New Zealand
There is a large group of uremic toxins called middle molecules that are currently poorly removed by dialysis strategies, and THERANOVA provides clinicians with the ability to remove these molecules for the very first time. If we can remove these molecules, reduce the risk of cardiovascular diseases and secondary immune deficiency, our patients will surely do better.
THERANOVA is a major gamechanger for us and our patients
Dr. Hutchison is currently part of a clinical team in Australia and New Zealand who is running a multicentre study providing safety and efficacy data looking at HDx Therapy in nearly 90 patients.
An Australian and new zealand research team investigates the impact of albumin and large middle molecules on renal patients
Patients are burdened by cardiovascular diseases, chronic inflammation and the consequences of secondary immune deficiency which translates tinto high infection rates that can lead to hospitalization for patients.
The Team is looking over a six-month period to see firstly that patients don't become harmed through excessive albumin loss on the dialyser and we will secondly be
looking at its efficiency for clearing large middle molecules. Specifically, the Team will be studying lambda free light chain as one of the largest molecules in this class of toxins.
This study started early in 2017 with results expected in 2018.
Stay updated on our latest clinical findings
- Our latest scientific findings
- New journal publications
- Ongoing trials and results
- And more on our global research partnerships.